Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Increasing Funding Supporting the Duchenne Muscular Dystrophy Therapeutics Market Growth"Supported by the funding provided by public and private organizations, global Duchenne Muscular Dystrophy Therapeutics Market is set to witness a high growth" says RNCOS
According to a new research report by RNCOS entitled, "Global Duchenne Muscular Dystrophy Therapeutics Market By Drug (Translarna, Emflaza, EXONDYS 51), By Therapeutic Approach (Steroid Therapy, Exon Skipping, Mutation Suppression) For instance, in February 2017, Exonics Therapeutics, Inc. received US$ 5 Million in seed financing from CureDuchenne Ventures, LLC, a subsidiary of the nonprofit CureDuchenne. The initial seed funding will allow Exonics to advance the preclinical research for Duchenne muscular dystrophy and other neuromuscular diseases. Furthermore, in Feb 2017, DMD Therapeutics, Inc., a start-up biotech company, received US$ 400,000 in initial funding from three foundations, Ryan's Quest, Michael's Cause, and Pietro's Fight, for developing proprietary therapeutics for Duchenne muscular dystrophy. DMD Therapeutics is now moving DMD-813 into drug development. Likewise, DMDfund, a non-profit organization founded by parents, relatives and friends of kids who have DMD, is dedicated to finding a cure for DMD by funding research. Moreover, Parent Project Muscular Dystrophy (PPMD), the biggest comprehensive nonprofit organization in the US, has invested over US$ 45 Million into Duchenne research which has leveraged over US$ 500 Million in additional funding. Furthermore, in September 2015, the Muscular Dystrophy Association (MDA), the world's leading nonprofit health agency, announced the award of 36 new research and development funds, with a sum of about US$ 10 Million. The new grants totaling US$ 2 Million will support 8 new research projects aimed at increasing the knowledge on DMD underlying mechanisms. Such developments have opened an array of opportunities for the treatment of Duchenne Muscular Dystrophy. For FREE SAMPLE of this report visit: http://www.rncos.com/ Check Related REPORTS on: http://www.rncos.com/ ABOUT RNCOS RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|